Text

Advance in the Treatment of Pediatric Leukemia

---

Abstract
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal anti

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

-

Publisher

: ., Basel, 2022

Collation

-

Language

ISBN/ISSN

9783036541686

Classification

NONE

Content Type

text

Media Type

computer

Carrier Type

online resource

Edition

-

Subject(s)

-

Specific Detail Info

-

Statement of Responsibility

Handgretinger, Rupert (editor)

Other Information

Cataloger

Siti

Source

-

Validator

-

Digital Object Identifier (DOI)

https://directory.doabooks.org/handle/20.500.12854/84555

Journal Volume

-

Journal Issue

-

Subtitle

-

Parallel Title

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment